A Phase 2, Randomised, Study of Radspherin(R) in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery.

This document provides information about a clinical study (NCT06504147) that aims to evaluate the safety and efficacy of a treatment for advanced ovarian cancer. The study is open to female patients aged 18 years and older who have been diagnosed with specific types of ovarian cancer. The eligibility criteria include factors such as disease stage, previous treatment, and overall health. The study will take place in multiple countries, including the United States, Belgium, Norway, Spain, and the United Kingdom. The document also includes administrative information about the study, such as contact details and study identifiers. [Extracted from the article]